Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia

Journal of Clinical Investigation(2022)10.1172/jci159579Source: DataRank Database

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 2.3. It has been cited 94 times, with 80 citing works in its 1-hop citation network.

N/A

2.3DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access94 citations · 80 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02845297

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (21 grants)Impact (FWCI 8.37)OA: goldTopics (49)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 30%Citation Network 70%

Base Score Contribution

0.683

From this paper's citation signal

Citation Network Contribution

1.6

From 62 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 80 citers.

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse
Leukemia202411 citations16 referencesContributes 0.155
Loss of CD28 expression associates with severe T-cell exhaustion in acute myeloid leukemia
Frontiers in Immunology202339 citations25 referencesContributes 0.148
Therapy response in AML: a tale of two T cells
Blood20244 citations11 referencesContributes 0.146
Single-cell sequencing unveils T-cell characteristic in acute myeloid leukemia
International Immunopharmacology20245 citations25 referencesContributes 0.072
AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML
Leukemia202415 citations48 referencesContributes 0.058

Authors (21)

Jayakumar Vadakekolathu ORCID,Francesco Mazziotta ORCID,Stephen Reeder,Tung On Yau ORCID,Rupkatha Mukhopadhyay ORCID

Live enrichment

PubMed:36099049 PMC:PMC9621145 OpenAlex:https://openalex.org/W4295423187

Qatar National Research Fund

Grant: NPRP8-2297-3-494

NIH/NCI

Grant: NIH/NCI 1U01CA232486

NIH/NCI

Grant: U01CA243072

Department of Defense Translational Team Science Award

Grant: CA180683P1

NIH/NCI

Grant: NIH/NCI P01CA225618

Nottingham Trent University

Grant: Health

Nottingham Trent University

Grant: Wellbeing Strategic Research Theme

NCI NIH HHS

Grant: P01 CA065493

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: P30 CA042014

NCI NIH HHS

Grant: T32 CA009666

NCI NIH HHS

Grant: U01 CA232486

NCI NIH HHS

Grant: P01 CA225618

NHLBI NIH HHS

Grant: K08 HL145116

NHLBI NIH HHS

Grant: R01 HL056067

National Institutes of Health

Grant: 5U01CA243072-05

Towards rational design of combination therapeutic targets

National Institutes of Health

Grant: 5K08HL145116-02

Probing Notch regulation of alloimmunity to uncover novel strategies for graft-versus-host disease control

National Institutes of Health

Grant: 3P30CA042014-30S2

Cancer Center Support Grant

National Institutes of Health

Grant: 1U01CA232486-01

Multispecific targeting incorporating cytokine receptor pathways in high risk pediatric acute leukemias to improve durability of adoptive cell therapy-induced remissions

National Institutes of Health

Grant: 5P01CA225618-03

Bone Marrow Transplantation in Human Disease

National Institutes of Health

Grant: 1S10RR026802-01

Univ of Utah Cell Sorter for Flow Cytometry Core

FWCI

8.37

Citation Percentile

1.0%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.jci.org/articles/view/159579/files/pdf

GOLDhttp://www.jci.org/articles/view/159579/files/pdf

publisherhttp://www.jci.org/articles/view/159579/files/pdf

publisherhttps://www.jci.org/articles/view/159579/files/pdf

journalhttps://doi.org/10.1172/jci159579

Fields of Study

Cancer Immunotherapy and BiomarkersSingle-cell and spatial transcriptomicsImmune cells in cancerMedicineBiology0301 basic medicine03 medical and health sciencesHumansLeukemia, Myeloid, AcutePrognosisImmunotherapyTumor MicroenvironmentCD8-Positive T-LymphocytesImmune System Diseases

MeSH Terms

HumansImmune System DiseasesImmunotherapyPrognosisLeukemia, Myeloid, AcuteCD8-Positive T-LymphocytesTumor Microenvironment

Keywords

Myeloid leukemiaMedicineImmune checkpointBlockadeImmunotherapyOncologyCD8Immune systemLeukemiaEffectorInternal medicineImmunologyCancer researchReceptorHematologyCellular senescenceCancer ImmunotherapyLeukemiasMyeloidRAcuteCD8-Positive T-LymphocytesPrognosisLeukemia, Myeloid, AcuteImmune System DiseasesTumor MicroenvironmentHumansClinical Medicine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being